Los inhibidores de SGLT2 son fármacos para la diabetes que además protegen el corazón y los riñones. Esa protección, no el pequeño efecto sobre el azúcar en sangre, es la razón por la que la clase se prescribe ahora ampliamente. Bloquean un transportador del riñón llamado SGLT2, de modo que entre 50 y 80 gramos de glucosa al día salen en la orina. El beneficio grande y repetido es la protección cardíaca y renal. En toda la clase, los dos resultados más constantes son mantener a los pacientes con insuficiencia cardíaca fuera del hospital y frenar la enfermedad renal crónica.
Varios de estos se sostienen incluso en personas sin diabetes. Su efecto sobre la muerte cardiovascular fue menos consistente entre ensayos. El interés en la longevidad es aparte y mucho más endeble, y se basa en un único resultado en animales sin ningún ensayo en humanos completado. También conllevan contrapartidas: cetoacidosis que puede ocurrir con un azúcar en sangre casi normal, infecciones genitales por hongos, depleción de volumen y una infección perineal rara y grave. Estos son fármacos de prescripción, que se inician con un prescriptor.
Findings & Outcomes
What It Is
SGLT2 inhibitors are oral diabetes drugs that block one kidney transporter, so glucose leaves in the urine. SGLT2 stands for sodium-glucose cotransporter 2, a protein in the proximal tubule of the kidney.
Three SGLT2 inhibitors carry most of the evidence: empagliflozin, dapagliflozin and canagliflozin, sold as Jardiance, Farxiga and Invokana. Their generic names all end in -gliflozin. They were approved to lower blood sugar, and large outcome trials changed that standing. Heart and kidney specialists now prescribe them mainly for organ protection.
The disease these drugs treat is largely manufactured, driven by ultra-processed food heavy in sugar, fat and salt. In the Nurses' Health Study, about 90% of type 2 diabetes cases traced to modifiable factors like diet and weight.
What It Does
The result that changed the class came from EMPA-REG OUTCOME. The trial set out only to show that empagliflozin did not harm the heart. Instead, in people with type 2 diabetes and established heart disease, it cut death from cardiovascular causes by 38% and death from any cause by 32%. That cut in cardiovascular death held up when the separate class trials were pooled, but its size varied from one to the next. Unlike the heart-failure and kidney results, it is not a uniform property of the class.
Two benefits then repeat across the class in separate randomized trials: fewer hospital admissions for heart failure, and a slower loss of function in chronic kidney disease. DAPA-HF, DAPA-CKD and CREDENCE are the trials that pinned them down.
The pivotal trials were paid for by the companies that sell the drugs. Boehringer Ingelheim and Eli Lilly funded EMPA-REG OUTCOME; AstraZeneca funded DAPA-HF and DAPA-CKD; Janssen funded CREDENCE and CANVAS. That funding does not overturn the findings, because the same benefits repeat across separate drugs, separate companies and independent analyses. Manufacturer-funded trials also tend to report effects at the favorable edge.
A separate and far thinner line of evidence links the class to the biology of aging, and it rests on a single animal result.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Heart And Vascular
La empagliflozina redujo la muerte cardiovascular en un 38 % y la muerte por cualquier causa en un 32 % (EMPA-REG)
En personas con diabetes tipo 2 que ya tenían enfermedad cardíaca, la empagliflozina redujo la tasa de muerte por causas cardíacas en casi dos quintos y redujo las hospitalizaciones por insuficiencia cardíaca en aproximadamente un tercio.
En EMPA-REG OUTCOME, la empagliflozina redujo la muerte cardiovascular en un 38 % (HR 0.62), la muerte por cualquier causa en un 32 % (HR 0.68) y la hospitalización por insuficiencia cardíaca en un 35 % (HR 0.65) a lo largo de una mediana de 3.1 años en adultos con diabetes tipo 2 y enfermedad cardiovascular establecida. Measured in: 7,020 adults with type 2 diabetes and established cardiovascular disease, mean age 63, about 71% men, median follow-up 3.1 years.. El ensayo incluyó a personas que ya tenían enfermedad cardiovascular, por lo que muestra beneficio en ese grupo de mayor riesgo, no en la población general, y los participantes eran aproximadamente un 71 % hombres.
Who this may not transfer to:Trial population was people with type 2 diabetes and established heart disease, about 71% men, so the benefit is shown in that higher-risk group.
The study · 1
Zinman et al., empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME) · N Engl J Med 2015;373:2117-2128
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
La dapagliflozina redujo el empeoramiento de la insuficiencia cardíaca o la muerte cardiovascular en un 26 %, con o sin diabetes (DAPA-HF)
En personas con un corazón debilitado, la dapagliflozina redujo la tasa de empeoramiento de la insuficiencia cardíaca o de muerte por causas cardíacas en aproximadamente un cuarto, y funcionó igual de bien en quienes no tenían diabetes.
En DAPA-HF, la dapagliflozina redujo el compuesto principal de empeoramiento de la insuficiencia cardíaca o muerte cardiovascular en un 26 % (HR 0.74) a lo largo de una mediana de 18.2 meses en personas con insuficiencia cardíaca y fracción de eyección reducida, y el beneficio fue consistente tuvieran o no diabetes tipo 2. Measured in: 4,744 adults with heart failure and reduced ejection fraction, about 42% with type 2 diabetes, about 77% men, median follow-up 18.2 months.. El ensayo estudió específicamente la insuficiencia cardíaca con fracción de eyección reducida, y los participantes eran aproximadamente un 77 % hombres, por lo que el equilibrio por sexo está sesgado.
Who this may not transfer to:Heart failure with reduced ejection fraction, about 77% men; the benefit held with and without diabetes.
The study · 1
McMurray et al., dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF) · N Engl J Med 2019;381:1995-2008
Toda la clase reduce los infartos, la hospitalización por insuficiencia cardíaca y el deterioro renal (ensayos combinados)
Al combinar los grandes ensayos, toda la clase reduce de forma fiable los infartos y los accidentes cerebrovasculares, las hospitalizaciones por insuficiencia cardíaca y el deterioro renal, por lo que se trata de una propiedad de la clase y no de un único fármaco.
Un metaanálisis de seis grandes ensayos de resultados con inhibidores de SGLT2 en diabetes tipo 2 (46,969 pacientes) encontró que la clase reducía los eventos cardiovasculares adversos mayores, la hospitalización por insuficiencia cardíaca y la progresión de la enfermedad renal, siendo los beneficios sobre la insuficiencia cardíaca y el riñón los más consistentes entre los fármacos; la reducción de la muerte cardiovascular fue significativa en general, pero varió entre los ensayos. Measured in: Pooled participants from large cardiovascular and renal outcome trials of SGLT2 inhibitors in type 2 diabetes.. Los ensayos combinados incluyeron a personas con diabetes tipo 2 con riesgo cardiovascular o renal elevado, por lo que el efecto de clase está establecido en esa población, no en poblaciones generales de bajo riesgo o no diabéticas.
Who this may not transfer to:Pooled from diabetes outcome trials at elevated cardiovascular or kidney risk; not tested in low-risk or non-diabetic general populations.
The study · 1
McGuire et al., association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis · JAMA Cardiol 2021;6:148-158
Kidney Disease
La dapagliflozina redujo la progresión de la enfermedad renal y la muerte relacionada en un 39 % (DAPA-CKD)
En personas con enfermedad renal crónica, la dapagliflozina ralentizó la pérdida de función renal y redujo el riesgo de insuficiencia renal en aproximadamente dos quintos, y también ayudó a quienes no tenían diabetes.
En DAPA-CKD, la dapagliflozina redujo el compuesto principal de una caída sostenida de la función renal, la enfermedad renal terminal, o la muerte renal o cardiovascular en un 39 % (HR 0.61) en personas con enfermedad renal crónica, con beneficio tuvieran o no diabetes tipo 2. Measured in: 4,304 adults with chronic kidney disease, about 67% with type 2 diabetes, about 67% men, trial stopped early for benefit.. El ensayo se detuvo antes de tiempo por beneficio claro, lo que puede sobreestimar modestamente el tamaño del efecto, y los participantes eran aproximadamente un 67 % hombres.
Who this may not transfer to:Chronic kidney disease, about 67% men; the benefit held with and without diabetes.
The study · 1
Heerspink et al., dapagliflozin in patients with chronic kidney disease (DAPA-CKD) · N Engl J Med 2020;383:1436-1446
La canagliflozina redujo un 30 % la insuficiencia renal y la muerte relacionada en la nefropatía diabética (CREDENCE)
En personas con diabetes cuyos riñones ya perdían proteínas, la canagliflozina redujo el riesgo de insuficiencia renal y muerte relacionada en aproximadamente un tercio.
En CREDENCE, la canagliflozina redujo el criterio de valoración compuesto primario de enfermedad renal terminal, duplicación de la creatinina sérica o muerte renal o cardiovascular en un 30 % (HR 0.70) en personas con diabetes tipo 2 y enfermedad renal crónica albuminúrica. Measured in: 4,401 adults with type 2 diabetes and albuminuric chronic kidney disease, about 66% men, trial stopped early for benefit.. Este ensayo se realizó en personas con diabetes y daño renal preexistente, por lo que establece un beneficio en esa población, y se detuvo antes de lo previsto por eficacia.
Who this may not transfer to:People with type 2 diabetes and albuminuric kidney disease, about 66% men.
The study · 1
Perkovic et al., canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE) · N Engl J Med 2019;380:2295-2306
How it works
Bloquear la SGLT2 en el riñón vierte de 50 a 80 gramos de glucosa al día en la orina
Estos fármacos impiden que el riñón recupere la glucosa, de modo que en lugar de volver a la sangre, sale en la orina, lo que reduce el azúcar en sangre sin necesitar más insulina.
Los inhibidores de la SGLT2 bloquean el cotransportador de sodio-glucosa 2 en el túbulo proximal del riñón, que normalmente reabsorbe aproximadamente el 90 % de la glucosa filtrada. Bloquearlo hace que se excreten aproximadamente de 50 a 80 gramos de glucosa al día en la orina, reduciendo el azúcar en sangre independientemente de la insulina, con una diuresis osmótica leve y pequeñas reducciones en el peso y la presión arterial. La reducción del azúcar en sangre es modesta y no explica la magnitud de los beneficios cardíacos y renales, que se cree que provienen de la reducción de la sobrecarga de líquidos, la disminución de la presión en el filtro renal, y un cambio hacia el metabolismo de cetonas.
Who this may not transfer to:Mechanism of the drug class; applies to anyone taking one.
The study · 1
Peters et al., euglycemic diabetic ketoacidosis: a potential complication of treatment with SGLT2 inhibition · Diabetes Care 2015;38:1687-1693
Blood Sugar
La empagliflozina redujo la HbA1c solo en aproximadamente 0.3 a 0.5 puntos, un efecto glucémico modesto
La caída del azúcar en sangre a largo plazo que producen estos fármacos es pequeña, menor de lo que aporta la metformina o un fármaco GLP-1, y no explica las ganancias cardíacas y renales.
En EMPA-REG OUTCOME, la empagliflozina redujo la HbA1c en aproximadamente 0.3 a 0.5 puntos porcentuales más que el placebo a lo largo del ensayo, junto con pequeñas reducciones en el peso corporal y la presión arterial, un efecto glucémico modesto en comparación con la magnitud del beneficio cardiovascular. Measured in: 7,020 adults with type 2 diabetes and established cardiovascular disease, mean age 63, about 71% men.. Esta es la diferencia de HbA1c entre grupos en un ensayo de resultados cardiovasculares donde se ajustó el tratamiento de base para la diabetes, por lo que refleja el modesto efecto glucémico adicional, no una comparación cara a cara de reducción de la glucosa.
Who this may not transfer to:Add-on glucose effect measured in a diabetes cardiovascular trial, about 71% men.
The study · 1
Zinman et al., empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME) · N Engl J Med 2015;373:2117-2128
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Longevity And Mortality
La canagliflozina prolongó la esperanza de vida media de los ratones machos en aproximadamente un 14 %, sin efecto en las hembras
En un estudio animal riguroso, una dieta con canagliflozina permitió que los ratones machos vivieran en promedio un 14 % más, mientras que las ratonas hembras no obtuvieron ningún beneficio.
En el Interventions Testing Program, un estudio riguroso multicéntrico en ratones genéticamente heterogéneos, la canagliflozina prolongó la esperanza de vida media en machos en aproximadamente un 14 %, pero no tuvo un efecto significativo en la esperanza de vida de las hembras. Se trata de un resultado en roedores y el beneficio apareció solo en machos, por lo que no establece ningún efecto sobre la esperanza de vida humana y no se traslada a las hembras ni siquiera a nivel animal.
Who this may not transfer to:Rodent result in male mice only; it does not transfer to humans, or to females even at the animal level.
The study · 1
Miller et al., canagliflozin extends life span in genetically heterogeneous male but not female mice · JCI Insight 2020;5:e140019
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Ningún ensayo en humanos completado muestra que estos fármacos prolonguen la esperanza de vida sana
No existe ningún ensayo en humanos que muestre que estos fármacos ayuden a las personas sanas a vivir más tiempo; los beneficios probados en humanos se refieren a personas que ya padecen una enfermedad cardíaca, renal o de la glucemia.
Ningún ensayo aleatorizado completado evalúa un inhibidor de SGLT2 para prolongar la esperanza de vida sana o el período de vida saludable en personas. La evidencia en humanos establece reducciones en los resultados de enfermedad cardiovascular y renal en personas que ya padecen esas afecciones, no una prolongación de la esperanza de vida en adultos sanos. El interés en la longevidad se basa en un único resultado de esperanza de vida animal en ratones machos y en el mecanismo, sin datos de resultados en humanos para un uso orientado al envejecimiento saludable.
Who this may not transfer to:No human outcome data for a healthy-aging use; the proven human benefits are in people who already have heart, kidney or blood sugar disease.
The study · 1
Miller et al., canagliflozin extends life span in genetically heterogeneous male but not female mice · JCI Insight 2020;5:e140019
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
How It Works
Anatomy
1What SGLT2 does, and what blocking it means
SGLT2 sits in the proximal tubule of the kidney and normally reclaims filtered glucose back into the blood. These drugs block it, so that glucose passes into the urine. Beyond lowering blood sugar, the loss pulls a little water and sodium out too. That produces small drops in weight and blood pressure.
2Why the heart and kidney benefits are larger than the glucose effect
The glucose effect is modest, so it does not explain the heart and kidney results. Three ideas lead. Mild fluid loss eases the load the heart must pump against. Lower pressure inside the kidney filter protects it over time. A shift toward burning ketones may give the heart a more efficient fuel. Which matters most is still being worked out, though the outcome data are large and consistent.
3The longevity question
The Interventions Testing Program, a rigorous multi-site animal aging study, found canagliflozin extended median lifespan in male mice by about 14% and did nothing measurable in females. The proposed reasons include the daily loss of glucose calories acting as a mild caloric restriction, and a metabolic switch toward ketones. No completed human trial tests any of these drugs for healthy aging, so this remains a hypothesis grounded in one animal result.
The kidney filters roughly 180 grams of glucose a day and, in a healthy person, reabsorbs nearly all of it. About 90% of that reabsorption runs through SGLT2, so blocking it lets 50 to 80 grams a day leave in the urine. That lowers blood sugar without pushing the pancreas to release more insulin. For the metabolic system these drugs act on, see insulin and glucose handling.
How to Approach It
The strongest evidence for these drugs is in heart failure, chronic kidney disease and type 2 diabetes. What to weigh before the longevity idea comes up:
The foundations of metabolic and cardiovascular health are exercise, whole foods, sleep and keeping muscle, and no drug substitutes for them. See [resistance training](/go/integrative/practice/resistance-training) for holding muscle with age and [sleep environment](/go/integrative/practice/sleep-environment) for the rest of the foundation.
For heart failure, chronic kidney disease and type 2 diabetes, these drugs have large randomized trials behind them. This is the core of what they are for.
With your prescriber, plan to pause the drug during serious illness, dehydration or before surgery. That single step heads off the most dangerous situation on the label.
For a healthy person without heart, kidney or blood-sugar disease, taking one to slow aging runs ahead of the evidence. So far that evidence is one mouse study, with no completed human trial and no established dose. Anyone drawn to it for aging can raise it with a prescriber before acting.
Go Deeper
- Insulin and glucose handling: how the body regulates blood sugar, and why moving glucose out of the blood matters.
- The biology of aging: the science behind the longevity claim.
- Metformin: the other old diabetes drug at the center of the same longevity question.
- GLP-1 Medications: the newer diabetes and weight drugs weighed alongside this class.
- Resistance training: the free, self-directed lever for holding muscle and metabolic health with age.
- Sleep environment: the rest of the foundation no pill replaces.
The Chinese Medicine View
SGLT2 inhibitors are products of modern chemistry, developed over roughly the past 20 years. No classical Chinese text lists one, no channel, no temperature, no flavor, and no traditional formula that contains it.
Classical Chinese medicine does describe a pattern that maps loosely onto diabetes: Xiao Ke, the wasting-and-thirsting disorder. It reads the heavy urination and constant thirst of that pattern as Yin depletion with Heat, a state the tradition works to resolve.
From that starting point the tradition would raise a caution. These drugs deliberately increase the loss of a refined substance, glucose, through the urine, and pull body fluid out along with it. A tradition built around preserving fluids and Yin would see deliberately causing that loss, in someone already dry and thirsty, as the wrong move. The volume-depletion and dehydration risk on the label lines up with that concern.
The tradition would not read a deliberate loss of glucose as strengthening anything. It treats these drugs as acting on the downstream picture: high blood sugar, heart strain, kidney decline. Its own aim, a body that transforms and holds its own fluids, is a different task the drug does not address. The case for the drugs rests on their own trials. For heart and kidney disease, those trials are extensive. Nothing here suggests any herb or formula reproduces what they do.
Cautions
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Las infecciones genitales por hongos aumentan tanto en hombres como en mujeres, con mayor frecuencia al principio
En el programa CANVAS, la canagliflozina aumentó las infecciones micóticas genitales tanto en mujeres como en hombres en comparación con placebo, un efecto constante de verter glucosa en la orina y observado en toda la clase de fármacos. Las tasas provienen de una población con diabetes, y las infecciones genitales fueron frecuentes pero, en general, tratables, no graves.Neal et al., canagliflozin and cardiovascular and renal events in type 2 diabetes (CANVAS Program)
La cetoacidosis puede aparecer mientras la glucemia se registra cercana a lo normal, lo que facilita que pase desapercibida
Una serie de casos describió cetoacidosis diabética durante el tratamiento con inhibidores de SGLT2 mientras la glucemia se registraba cercana a lo normal, no marcadamente elevada, la llamada cetoacidosis euglucémica, precipitada por cirugía, enfermedad aguda, deshidratación, reducción de insulina e ingesta baja en carbohidratos. Se trata de una pequeña serie de casos, no de una tasa procedente de un ensayo controlado, por lo que establece que el evento ocurre y sus desencadenantes, no una incidencia precisa.Peters et al., euglycemic diabetic ketoacidosis: a potential complication of treatment with SGLT2 inhibition
La canagliflozina duplicó aproximadamente la amputación de miembros inferiores, 6.3 frente a 3.4 por 1000 pacientes-año (CANVAS)
En el programa CANVAS, la canagliflozina se asoció con aproximadamente el doble de tasa de amputación de miembros inferiores en comparación con placebo (6.3 frente a 3.4 por 1000 pacientes-año; HR 1.97), principalmente a nivel del dedo o el metatarso. Un ensayo renal posterior con canagliflozina no reprodujo la misma magnitud de la señal de amputación, por lo que el riesgo no está completamente establecido, y se estudió en una población con diabetes de alto riesgo.Neal et al., canagliflozin and cardiovascular and renal events in type 2 diabetes (CANVAS Program)
Fournier gangrene, a perineal infection: 55 postmarketing cases across the class
Una revisión de notificaciones poscomercialización identificó 55 casos de gangrena de Fournier, una infección necrosante del perineo, en personas que tomaban inhibidores de SGLT2 durante aproximadamente seis años, un evento raro pero grave observado en toda la clase de fármacos. These are spontaneous postmarketing reports, which cannot establish an incidence rate or prove the drug caused each case, but the signal was consistent enough to prompt a class warning.Bersoff-Matcha et al., Fournier gangrene associated with SGLT2 inhibitors: a review of spontaneous postmarketing cases
A prescription drug, and the decision sits with a clinician
These are prescription medicines. Whether one fits, and how it interacts with your kidney function, blood pressure and other medicines, is a decision made with a prescriber. No dose is given, because there is no safe general dose outside the diseases these drugs are approved to treat.
Ketoacidosis at near-normal blood sugar
These drugs can cause diabetic ketoacidosis, a dangerous buildup of acid in the blood. It can happen while blood sugar reads close to normal. The risk rises around surgery, serious illness, dehydration, heavy alcohol use, and very low-carbohydrate eating. The standard guidance is to pause the drug during those situations, a plan a prescriber sets in advance.
Genital yeast and urinary infections
Because the drugs put sugar into the urine, they raise the rate of genital yeast infections in men and women, most often early in treatment. They can also contribute to urinary tract infections. These are usually treatable, and common enough to expect and plan for before starting.
Volume depletion and low blood pressure
The mild diuretic effect can tip into dehydration and low blood pressure, especially in older adults, in people already on other diuretics, and during illness with poor fluid intake. Staying well hydrated and reviewing other blood-pressure and fluid medicines with a prescriber is part of using these drugs safely.
Fournier gangrene, rare but serious
A rare but severe infection of the tissue around the genitals and perineum, called Fournier gangrene, has been reported across this drug class in postmarketing surveillance. It needs emergency care.
The amputation signal with canagliflozin
In the CANVAS trial, canagliflozin was linked to about twice the rate of lower-limb amputation, mostly of toes and the mid-foot. Later trials of the same drug did not show an effect that large, so the picture is not settled. It is still a specific reason to raise foot care and any existing foot problems with a prescriber.
Not a do-it-yourself longevity drug
No completed human trial establishes a benefit or a dose for these drugs as a way to slow aging in a healthy person. The research is a single result in mice. A prescriber can weigh the trade-offs for an individual case.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
When to See Someone
Most people who take these drugs for the right reason do well. Two problems are emergencies because they can look milder than they are. If either fits, get seen without waiting.
- Nausea, vomiting, abdominal pain, deep or rapid breathing, unusual drowsiness or confusion, even when a home glucose reading looks normal. This can be diabetic ketoacidosis. The normal-looking blood sugar is what makes it easy to miss, so get urgent assessment.(seek urgent care)
- Severe pain, swelling, redness or tenderness of the genitals or the perineum, especially with fever or feeling very unwell. This can be Fournier gangrene, a fast-spreading infection. Get emergency care.(seek urgent care)
These drugs have a strong record in heart and kidney disease. Both are treatable when caught early and dangerous when missed. Any change to a prescribed medicine goes through your prescriber.
Common Questions
What do SGLT2 inhibitors actually do?
They block the kidney's reabsorption of glucose, so it leaves in the urine. Normally the kidney reclaims almost all the glucose it filters through the SGLT2 transporter. These drugs block that transporter, so 50 to 80 grams of glucose leave in the urine each day. That lowers blood sugar and produces small drops in weight and blood pressure.
The larger reason they are prescribed is protection of the heart and kidneys, beyond what the blood-sugar change alone would predict.
Do they help people who do not have diabetes?
Yes, for two conditions. In DAPA-HF, dapagliflozin cut worsening heart failure or cardiovascular death in people with a weak heart. In DAPA-CKD, it slowed chronic kidney disease. In both trials the benefit held whether or not the person had diabetes. That is why cardiologists and kidney specialists prescribe them beyond diabetes care. The benefit is established in people who already have heart or kidney disease, not in an otherwise healthy person.
Do SGLT2 inhibitors extend lifespan?
In people, that is not known. The evidence is one animal result: in the Interventions Testing Program, the drug raised median survival in male mice by roughly 14%, with no measurable effect in females. The proposed reasons are the daily loss of glucose calories and a shift toward burning ketones. No completed human trial tests any of these drugs for slowing aging. The established human benefit is protection of the heart and kidney in people who already have disease.
What are the main risks?
Ketoacidosis is the one that can begin while blood sugar reads near normal, so the drugs are paused around illness and surgery. Genital yeast infections are common early, from the sugar in the urine. The mild diuretic effect can also cause volume depletion and low blood pressure, most of all in older adults on other diuretics. Rarer and serious is Fournier gangrene, a fast-spreading infection in the genital and perineal tissue. Canagliflozin also carried an amputation signal in the CANVAS trial.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 13 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.